Company Overview of Regen BioPharma Inc.
Regen Biopharma, Inc., a biotechnology company, focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrow; HemaXellerate II, a donor endothelial cell based therapeutic product; and dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer. The company was founded in 2012 and is based in La Mesa, California. Regen Biopharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.
4700 Spring Street
La Mesa, CA 91942
Founded in 2012
Key Executives for Regen BioPharma Inc.
Chairman, Chief Executive Officer, President, Principal Accounting Officer, Treasurer, Secretary, Chairman of Bio-Matrix Scientific Group and Chief Executive Officer of Bio-Matrix Scientific Group
Total Annual Compensation: $300.0K
Chief Scientific Officer, Director of Research and Director
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2014.
Regen BioPharma Inc. Key Developments
Regen Biopharma, Inc. Completes in Life Portion of Experiments Requested by FDA for HemaXellerate Pre-Clinical Study
Jul 21 15
Regen BioPharma Inc. announced positive preliminary safety results from the in life portion of an experimental study requested by the US Food and Drug Administration assessing toxicity in mice treated with high doses of HemaXellerate, a proprietary therapy under development by Regen Biopharma Inc. After a 14 day observation period, male and female mice administered with higher than 10-fold the proposed human dose on a per kilogram basis exhibited no adverse effects.Â Regen expects to receive an audited report on full completion of the experiments in mid-September. The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
Regen Biopharma, Inc. Reports Successful Dosing of Hemaxellerate in FDA-Requested GLP Animal Study
Jul 9 15
Regen BioPharma Inc. reported the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate, the company's proprietary aplastic anemia cell therapy drug candidate. The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. The purpose of the study is to evaluate whether administration of more than ten-fold the proposed clinical dose of cells in mice on a per weight basis will cause any adverse effects on the experimental mice. The study was conducted in response to the last material question posed by the US Food and Drug Administration (FDA) to Regen with regard to Regen's proposed clinical trial evaluating HemaXellerate in patients with aplastic anemia. Safety parameters evaluated will include: weight changes, alteration in cellular structures of the major organs, organ function, serum biochemistry, and hematology tests. The initial observation will take 14 days, after which data will be collected, analyzed, and submitted to the FDA. Charles River Laboratories anticipates submission to Regen BioPharma Inc. of an audited draft report by September 16, 2015.
Regen BioPharma Inc. Enters into License Agreement with Zander Therapeutics, Inc
Jun 26 15
Regen BioPharma Inc. entered into an agreement with Zander Therapeutics Inc. (Zander) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen (License IP) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a wholly owned subsidiary of Entest Biomedical Inc. Pursuant to the Agreement, Zander shall pay to Regen one-time, non-refundable, upfront payment of $100,000 as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of $100,000 on the first anniversary of the effective date of the Agreement and each subsequent anniversary. The abovementioned payments may be made, at Zander's discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance. Pursuant to the Agreement, Zander shall pay to Regen royalties equal to 4% of the Net Sales, as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay Regen10% of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees (excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to Regen minimum annual royalties of $10,000 payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed $10,000. If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve month period after Zander's first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to Regen with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 12, 2015
March 6, 2015
March 5, 2015